LB Pharmaceuticals Inc (LBRX) stock
LBRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$40.06−0.24 (-0.60%)
Close on Nov 18, 2026Market cap $1.29BP/E –Yield –
LB Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
LB Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $69.69M, up 312.8% year over year. For fiscal 2025 it was $16.74M, down 67.3% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.74M | -67.3% |
| FY2024 | Dec 31, 2024 | $51.17M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $44.15M | +1723.5% |
| Q1 FY2026 | Mar 31, 2026 | $14.65M | +328.1% |
| Q4 FY2025 | Dec 31, 2025 | $8.48M | +2156.1% |
| Q3 FY2025 | Sep 30, 2025 | $2.42M | -77.3% |
| Q2 FY2025 | Jun 30, 2025 | $2.42M | – |
| Q1 FY2025 | Mar 31, 2025 | $3.42M | – |
| Q4 FY2024 | Dec 31, 2024 | $376.00K | – |
| Q3 FY2024 | Sep 30, 2024 | $10.66M | – |
See a number that looks wrong?